Earning Growth Points can win an iPhone 16?
Gate Post Growth Points Summer Lucky Draw Round 1️⃣ 1️⃣ Is Live!
🎁Prize pool over $10,000! Win iPhone 16 Pro Max 512G, exclusive Gate merch, popular tokens & more!
Try your luck now 👉 https://www.gate.com/activities/pointprize?now_period=11
How to earn Growth Points fast?
1️⃣ Go to [Post], tap the icon next to your avatar to enter [Community Center]
2️⃣ Complete daily tasks like posting, commenting, liking, and chatting to earn points
New feature this round: “Fragment Exchange”! Collect fragments to redeem exclusive Gate merch!
100% chance to win
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.